[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Fujii S, Takakura K, Matsumura N, Higuchi T, Yura S, Mandai M, Baba T: Precise anatomy of the vesico-uterine ligament for radical hysterectomy. Gynecol Oncol; 2007 Jan;104(1):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty-nine patients (TNM nomenclature: pTIb: 39, pT2a: 5, pT2b: 7, after trans-arterial anticancer-drug infusion treatment for the cervical cancer: 8) underwent this meticulous operation.
  • RESULTS: After complete separation of the uterine artery and superficial uterine vein from the ureter, we could identify the genuine connective tissue of the anterior leaf of the VUL in which we isolate and divide a distinct bundle of blood vessels: the cervicovesical vessels that cross over the ureter from the bladder to the cervix.
  • The posterior leaf of the VUL is the tissue residing under the ureter connecting the posterior wall of the bladder and the lateral cervix/upper lateral vagina.
  • The division of these veins could separate the urinary bladder with ureters completely from the lateral cervix and upper vagina.
  • [MeSH-minor] Arteries / anatomy & histology. Arteries / surgery. Blood Loss, Surgical / prevention & control. Female. Humans. Neoplasm Staging


2. Rübben H, Otto T: [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy]. Urologe A; 2001 Nov;40(6):464-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy].
  • The prognostic factors for infiltrating tumors established by the TNM system in 1997 include: Depth of infiltration, degree of differentiation, status of lymph nodes distant metastases.
  • Of the additional factors investigated, only tumor size and hydronephrosis appear to be of prognostic significance.
  • In cases of carcinoma of the urinary bladder without metastases (T2-4,N0,M0), radical cystectomy is the therapy of choice.
  • A preceding neoadjuvant systemic regimen of chemotherapy with three cycles of M-VAC (methotrexate, vinblastine, adriamycin, cisplatin) significantly improves the survival rate.
  • In patients with locally advanced urinary bladder carcinoma, however, adjuvant systemic chemotherapy with M-VAC after cystectomy and lymphadenectomy offers no advantages for survival.
  • Quality of life in patients with metastatic bladder cancer disease is improved by new cytotoxic drugs, i.e. gemcitabine or taxanes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / surgery. Neoadjuvant Therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Lymph Node Excision. Methotrexate / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760352.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


3. Lerner SP: The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma. Curr Treat Options Oncol; 2009 Aug;10(3-4):267-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An extended node dissection may include the distal aortic and vena caval nodes, bilateral common iliac, and pre-sacral nodes, which receive direct lymphatic drainage from the posterior bladder and trigone.
  • This approach sets up the cystectomy, maximizes sensitivity for detection of nodal metastasis, assures optimum local pelvic cancer control, and accurately identifies those high-risk patients with node metastases who may benefit from adjuvant chemotherapy.
  • The current TNM staging system accounts for the number and size of node metastases and may be improved by incorporating lymph node density, which is a composite variable incorporating the number of positive nodes and number of nodes retrieved--a possible surrogate for the extent of the node dissection.
  • Innovations in imaging including novel MRI contrast agents and lymphoscintigraphy may improve the pre-treatment and intra-operative identification of node metastases and lymphatic anatomy.
  • Minimally invasive surgical techniques including robotic-assisted laparoscopic cystectomy may improve peri-operative outcomes but must meet the standard of anatomic node dissection and long-term cancer control afforded by the gold standard of anatomic radical cystectomy and bilateral pelvic and iliac node dissection.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Contrast Media / pharmacology. Humans. Magnetic Resonance Imaging. Medical Oncology / methods. Medical Oncology / trends. Neoplasm Staging. Prognosis. Radionuclide Imaging / methods. Robotics. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2009 Mar;16(3):274-8; discussion 278 [19087211.001]
  • [Cites] J Urol. 2008 Jan;179(1):34-45 [17997425.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4 [17698113.001]
  • [Cites] J Urol. 2003 Mar;169(3):943-5 [12576818.001]
  • [Cites] J Urol. 2003 Jul;170(1):35-41 [12796639.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201 [15939530.001]
  • [Cites] J Urol. 1982 Jul;128(1):34-6 [7109065.001]
  • [Cites] J Urol. 2001 Dec;166(6):2295-6 [11696756.001]
  • [Cites] J Urol. 2009 Jun;181(6):2490-5 [19371902.001]
  • [Cites] Urology. 2008 Jul;72(1):128-32 [18455773.001]
  • [Cites] Urol J. 2008 Spring;5(2):94-8 [18592461.001]
  • [Cites] Radiology. 2004 Nov;233(2):449-56 [15375228.001]
  • [Cites] J Urol. 2003 Mar;169(3):946-50 [12576819.001]
  • [Cites] J Urol. 2001 Jul;166(1):19-23 [11435814.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2368-74 [17041887.001]
  • [Cites] Eur Urol. 2008 Sep;54(3):690-1 [18792446.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Feb;19(1):71-4 [19288592.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Urol. 2004 May;171(5):1830-4 [15076287.001]
  • [Cites] BJU Int. 2009 May;103(10):1359-62 [19076140.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):369-75 [17762633.001]
  • [Cites] J Urol. 1993 Apr;149(4):758-64; discussion 764-5 [8455238.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] BJU Int. 2000 May;85(7):817-23 [10792159.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2253-7 [14634391.001]
  • [Cites] World J Urol. 2009 Feb;27(1):27-32 [19020882.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):806-12 [18085612.001]
  • [Cites] J Urol. 2004 Jan;171(1):139-44 [14665862.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):121-6 [18165646.001]
  • [Cites] J Urol. 2007 Mar;177(3):876-81; discussion 881-2 [17296365.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1809-12 [15540725.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1818-21 [15540728.001]
  • [Cites] Eur Urol. 2007 Dec;52(6):1708-9 [17646045.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):2015-9; discussion 2020 [9817313.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1286-90 [15371825.001]
  • [Cites] J Urol. 2006 Jan;175(1):84-8; discussion 88-9 [16406877.001]
  • (PMID = 19565335.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  • [Number-of-references] 39
  •  go-up   go-down


Advertisement
4. Wülfing C, Eltze E, Von Struensee D, Wülfing P, Bode ME, Bettendorf O, Piechota H, Hertle L: [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]. Aktuelle Urol; 2004 Aug;35(4):331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
  • We analyzed Cox-2-expression in bladder cancer and its implications on clinical parameters.
  • No association was found with TNM-staging and histological grading, but a significant relation to the histologic subtype (transitional vs. squamous cell carcinoma, p = 0.038) was present.
  • CONCLUSIONS: Cox-2-expression was found in the majority of invasive bladder tumors.
  • Cox-2 seems to be an interesting molecular target for the diagnosis and therapy of bladder cancer.
  • Further experimental and clinical studies are warranted to elucidate whether Cox-2-inhibition can serve as an additive therapy to chemotherapy of bladder cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Carcinoma, Transitional Cell / enzymology. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / analysis. Isoenzymes / antagonists & inhibitors. Prostaglandin-Endoperoxide Synthases / analysis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cystectomy. Disease-Free Survival. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Membrane Proteins. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Analysis. Time Factors. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15459875.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Walterhouse D, Watson A: Optimal management strategies for rhabdomyosarcoma in children. Paediatr Drugs; 2007;9(6):391-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fact that the tumor arises in a wide variety of primary sites, some of which are associated with specific patterns of local invasion, regional lymph node spread, and therapeutic response, requires physicians to be familiar with site-specific staging and treatment details.
  • The purpose of this review is to discuss 'optimal' management of this complicated tumor.
  • Since the tumor is relatively rare, requires highly specialized care, and important management questions remain to be answered, optimal management of rhabdomyosarcoma includes enrollment in clinical trials whenever possible.
  • Appropriate management begins with establishing the correct pathologic diagnosis, histologic subtype, primary site, extent of disease (International Society of Pediatric Oncology [SIOP]-TNM-Union Internationale Contre le Cancer stage or Intergroup Rhabdomyosarcoma Study Group [IRSG] stage), and extent of resection (IRSG group).
  • The surgical approach for rhabdomyosarcoma is to excise the primary tumor whenever possible without causing major functional or cosmetic deficits.
  • Wide excision is difficult in some primary sites and can be complicated by the fact that the tumor grows in a locally infiltrative manner so that complete resection is often neither possible nor medically indicated.
  • The cooperative groups reduce the dose of radiation based on the response of the tumor to chemotherapy and delayed primary resection to differing degrees.
  • Response-adjusted radiation administration may reduce the long-term effects of radiotherapy, such as bone growth arrest, muscle atrophy, bladder dysfunction, and induction of second malignant neoplasms; however, it may also be associated with an increased risk of tumor recurrence.
  • A backbone of vincristine and dactinomycin with either cyclophosphamide (VAC) or ifosfamide (IVA) has been established.
  • Risk-adapted treatment involves reducing or eliminating the alklyating agent for patients with the most favorable disease characteristics.
  • Clinical trials are ongoing to improve outcomes for higher risk patients; newer agents, such as topotecan or irinotecan, in combination with VAC or use of agents in novel ways are being investigated.
  • Acute and long-term toxicities associated with these chemotherapy regimens include myelosuppression, febrile neutropenia, hepatopathy, infertility, and second malignant neoplasms.
  • In the future, risk-adapted classification of rhabdomyosarcoma will likely be based on biologic features, such as the presence of chromosomal translocations or specific gene expression profiles.
  • [MeSH-minor] Child. Combined Modality Therapy. Diagnosis, Differential. Dose Fractionation. Humans. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7143-51 [16192598.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):563-7 [17006261.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Genet Epidemiol. 1995;12(5):467-74 [8557179.001]
  • [Cites] Neoplasia. 2006 May;8(5):394-401 [16790088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):497-504 [17084557.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):613-21 [11169946.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1697-706 [9586881.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3415-22 [16849756.001]
  • [Cites] Med Pediatr Oncol. 1999 Feb;32(2):88-92 [9950194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):427-32 [10661350.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1719-24 [15754335.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):309-16 [10693686.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jan-Feb;4(1):46-52 [11200490.001]
  • [Cites] Eur J Cancer. 2004 Aug;40(12):1878-85 [15288290.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2586-7 [15728222.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2454-68 [11413538.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):213-9 [11134215.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10 ):1894-901 [15143082.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):87-94 [10741300.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):8025-37 [16116481.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2796-803 [10561355.001]
  • [Cites] Semin Pediatr Surg. 2001 Aug;10(3):146-52 [11481652.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):134-8 [14752876.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28 [11597814.001]
  • [Cites] J Urol. 2006 Nov;176(5):2190-4; discussion 2194-5 [17070290.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1664-71 [15378498.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):227-31 [9028550.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2005 Aug 15;137C(1):72-7 [16010679.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1398-403 [15007087.001]
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):961-4 [10873044.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1432-8 [15817347.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2837-42 [17301234.001]
  • [Cites] Med Pediatr Oncol. 2001 Nov;37(5):442-8 [11745872.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):33-9 [3277029.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):197-204 [11134213.001]
  • [Cites] Med Pediatr Oncol. 1989;17(3):210-5 [2747593.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1027-38 [15234036.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):1-13 [10738297.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1177-84 [16682130.001]
  • (PMID = 18052409.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


6. Fritsche HM, Burger M, Ganzer R, Otto W, Denzinger S, Wieland WF: [Impact of comorbidity on perioperative mortality after radical cystectomy]. Aktuelle Urol; 2008 May;39(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TNM classification integrates the currently valid prognostic factors for tumour-specific survival after radical cystectomy due to bladder cancer.
  • But it does not contain the most important criteria for general survival.
  • Except for the comorbidity of the patients, none of the included parameters (initial symptoms, histology, indication for cystectomy, AJCC stadium, year of surgery, durance of surgery, surgeon, concomitant interventions, type of urinary diversion, blood loss and number of transfusions) showed a significant correlation to cause or postoperative time of death.
  • For the preoperative assessment of the health of the patient a multidisciplinary cooperation of urology, anaesthesia and general and/or internal medicine is necessary.
  • In the era of evidence-based medicine the personal judgement of the evaluating physician is not sufficient.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Health Status. Patient Care Team. Postoperative Complications / mortality. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Cause of Death. Comorbidity. Female. Hospital Mortality. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Urinary Diversion

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478497.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement